Biocon Biologics Ltd (BBL), a unit of Biocon Ltd (BIOCON), Monday said that the U.S. Food and Drug Administration or FDA has approved Yesintek, a biosimilar to Johnson and Johnson's, Stelara.
Yesintek is approved for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis.
Biocon had previously announced its settlement and licensing agreement with Janssen Biotech Inc., Janssen Sciences Ireland, and Johnson & Johnson to commercialize Yesintek no later than on February 22, 2025, upon approval from the FDA.
For comments and feedback: editorial@rttnews.com